 |
|
|
| |
ENDURANCE-3: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR COMPARED TO SOFOSBUVIR PLUS DACLATASVIR IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITHOUT CIRRHOSIS
|
| |
| |
Reported by Jules Levin
The International Liver Congress (EASL) - Amsterdam, The Netherlands 21 April 2017
Graham R Foster1, Edward Gane2, Armen Asatryan3, Tarik Asselah4, Peter J Ruane5, Stanislas Pol6, Fred Poordad7, Catherine A Stedman8, Gregory Dore9, Stuart K Roberts10, Kelly Kaita11, John Vierling12, Hugo E Vargas13, Jens Kort3, Chih-Wei Lin3, Ran Liu3, Teresa I Ng3, Federico J Mensa3
1Queen Mary University of London, Barts Health, London, United Kingdom; 2Liver Unit, Auckland City Hospital, Auckland, New Zealand; 3AbbVie Inc., North Chicago, IL, USA; 4Centre de Recherche sur l'Inflammation, Inserm UMR 1149, Université Paris Diderot, AP-HP Hôpital Beaujon, Clichy, France; 5Ruane Medical & Liver Health Institute, Los Angeles, California, United States; 6Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 7The Texas Liver Institute, San Antonio, Texas, United States; 8Christchurch Hospital and University of Otago, Christchurch, New Zealand; 9Kirby Institute, UNSW Australia and St Vincent's Hospital, Sydney, Australia; 10Alfred Hospital, Melbourne, Australia; 11University of Manitoba, Winnipeg, Manitoba, Canada; 12Baylor College of Medicine, Houston, Texas, United States; 13Mayo Clinic, Phoenix, Arizona, United States
AASLD: SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS - (11/14/16)
EASL: 100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS - (04/19/16)
EASL: HIGH SVR RATES WITH ABT-493 + ABT-530 CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION - (04/18/16)
|
| |
|
|
|
|
|
